Elevated serum uric acid affects myocardial reperfusion and infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Journal of Cardiovascular Medicine
Alessandro Mandurino-MirizziMaurizio Ferrario

Abstract

Elevated serum uric acid (eSUA) was associated with unfavorable outcome in patients with ST-segment elevation myocardial infarction (STEMI). However, the effect of eSUA on myocardial reperfusion injury and infarct size has been poorly investigated. Our aim was to correlate eSUA with infarct size, infarct size shrinkage, myocardial reperfusion grade and long-term mortality in STEMI patients undergoing primary percutaneous coronary intervention. We performed a post-hoc patients-level analysis of two randomized controlled trials, testing strategies for myocardial ischemia/reperfusion injury protection. Each patient underwent acute (3-5 days) and follow-up (4-6 months) cardiac magnetic resonance. Infarct size and infarct size shrinkage were outcomes of interest. We assessed T2-weighted edema, myocardial blush grade (MBG), corrected Thrombolysis in myocardial infarction Frame Count, ST-segment resolution and long-term all-cause mortality. A total of 101 (86.1% anterior) STEMI patients were included; eSUA was found in 16 (15.8%) patients. Infarct size was larger in eSUA compared with non-eSUA patients (42.3 ± 22 vs. 29.1 ± 15 ml, P = 0.008). After adjusting for covariates, infarct size was 10.3 ml (95% confidence interval 1.2-19.3 ml...Continue Reading

References

May 6, 2006·Stroke; a Journal of Cerebral Circulation·Michiel J BosMonique M B Breteler
Nov 13, 2009·International Journal of Cardiology·Maurizio FerrarioLuigi Tavazzi
Aug 9, 2011·Journal of Cardiovascular Pharmacology and Therapeutics·Andrew E Arai
Jan 21, 2012·International Journal of Cardiology·Giacomo LevantesiRoberto Marchioli
Jun 9, 2012·Journal of the American College of Cardiology·Franck ThunyPierre Croisille
Nov 24, 2012·Current Pharmaceutical Design·Davide GrassiClaudio Ferri
Apr 9, 2016·Journal of the American College of Cardiology·Gregg W StoneOri Ben-Yehuda
Nov 28, 2016·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Chaohuan LuoJidong Cheng
Jan 14, 2017·Cardiovascular Drugs and Therapy·Yao DaiJawahar L Mehta
May 10, 2017·International Journal of Cardiology·Marco MagnoniDomenico Cianflone

❮ Previous
Next ❯

Citations

Nov 25, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·ShiChun ShenJianLong Sheng
Apr 28, 2021·Angiology·Atalay DemirayMehmet Kanbay
Nov 21, 2021·European Journal of Clinical Investigation·Xiangming HuHaojian Dong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.